Hypertension combination therapy with rennin-angiotenzin system blockers

Česká verzia

Authors: M. Souček
Authors place of work: II. interní klinika Lékařské fakulty MU a FN u sv. Anny Brno, přednosta prof. MUDr. Miroslav Souček, CSc.
Published in the journal: Vnitř Lék 2009; 55(9): 719-723
Category: 80th Birthday - prof. MUDr. Miloš Štejfa, DrSc., FESC

Summary

Target blood pressure levels are not being achieved with the current hypertension treatment. Monotherapy that normalizes BP in about 20% of patients does not provide sufficient control to reach this goal and thus combination therapy is required. Results from recent clinical studies showed that a combination of an angiotenzin-converting enzyme inhibitor (ACEi) with a calcium channel blocker (CCB) provide better results and reduced incidence of cardiovascular events than a combination of a diuretic with an ACE inhibitor. Combination therapy based on rennin-angiotenzin system blockade: ACEi with a CCB, ACEi with a diuretic or angiotenzin receptor blocker (AT₁) with a diuretic as a first-line treatment of the stage 2 hypertension might lead to significantly better control of blood pressure than monotherapy.

Key words:
combination of hypertensives – angiotenzin-converting enzyme inhibitor – angiotenzin receptor blocker – diuretics – calcium channel blockers

Zdroje

1. Patel A and ADVANCE Collaborating Group. Effects of a fixed combination of perindopril and indapamide on macrovascular and microvascular aoutcomes in patients type 2 diabetes mellitus (the ADVANCE trial): a randomized controlled trial. Lancet 2007; 370: 829–840.

2. Beckett NS, Peters R, Fletcher AE et al. for the HYVET Study Group. Treatment of hypertension in patients 80 years of age or older. N Engl J Med 2008; 358: 1887–1898.

3. Jamerson K, Bakris GL, Dahlöf B et al. Exceptional early blood pressure control rates: The ACCOPMLISH trial. Blood Pressure 2007; 16: 80–86.

4. Weir MR, Neutel JM, Bhaumik A et al. The efficacy and safety of initial use of irbesartan/HCTZ fixed dose combination in hypertensive patients with a without high cardiovascular risk. J Clin Hypertens 2007; 9 (12 Suppl): 23–30.

5. Neutel JM, Franklin SS, Lapuerta P et al. A comparison of the efficacy and safety of irbesartan/HCTZ combination therapy with irbesartan and HCTZ monotherapy in the treatment of moderate hypertension. J Hum Hypertens 2007; 22: 266–274.

6. Pepine CJ, Handberg EM, Cooper-Dehoff RM et al for the INVEST investigators. A calcium antagonist versus a noncalcium antagonist hypertension treatment strategy for patients with corononary heart disease: The International Verapamil-Trandolapril Study (INVEST): A randomised controlled trial. JAMA 2003; 290: 2805–2816.

7. Nadar S, Lim HS, Beevers DG et al. Lipid lowering in hypertension and heart protection: observation from the Anglo-Scandinavian Cardiac Outcomes Trial (ASCOT) and the Heart Protection Study. J Hum Hypertens 2002; 16: 815–817.

8. Fox KM. Efficacy of perindopril in reduction of cardiovascular events among patients with stable coronary artery disease: randomised, double-blind, placebo controlled, multicentre trial (the EUROPA study). Lancet 2003; 362: 782–788.

9. Weber MA. New opportunities in cardiovascular patient management: A survey of clinical data on the combination of angiotensin-converting enzyme inhibitors and angiotensin receptor blockers. Am J Cardiol 2007; 100 (3A): 45J–52J.

10. Doulton TWR, He FJ, MacGregor GA. Systemic review of combined angiotensin-converting enzyme inhibitor and angiotensin receptor blockade in hypertension. Hypertension 2005; 45: 880–886.

11. Sleight P. The ONTARGET/TRANSCEND trial program: baseline data. Acta Diabetol 2005; 42 (Suppl 1): S50–S56.

12. Fischer ND, Hollenberg NK. Renin inhibition: What are the therapeutic opportunities? J Am Soc Nephrol 2005; 16: 592–599.

13. Oparil S, Yarows SA, Patel S et al. Efficacy and safety of combined use of aliskiren and valsartan in patients with hypertension: a randomized, double-blind trial. Lancet 2007; 370: 221–229.

14. Messerli FH, Bell DSH, Fonesca V et al. Body weight changes with beta blocker use: results from GEMINI. Am J Med 2007; 120: 610–615.

15. Bakris GL, Fonseca V, Katholi RE et al. Metabolic effects of carvedilol vs metoprolol in patients with type 2 diabetes mellitus and hypertension: a randomized controlled trial. JAMA 2004; 292: 2227–2236.